Vivek Garipalli - Jan 7, 2025 Form 4 Insider Report for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Role: Director, 10%+ Owner
Signature: /s/Peter J. Rivas as attorney-in-fact for Vivek Garipalli
Stock symbol: CLOV
Transactions as of: Jan 7, 2025
Transactions value $: -$6,015,474
Form type: 4
Date filed: 1/10/2025, 04:34 PM
Previous filing: Aug 13, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CLOV	Class A Common Stock	Options Exercise	$0	+1.67M	+118.57%	$0.00	3.08M	Jan 7, 2025	Direct	F1, F2
transaction	CLOV	Class A Common Stock	Tax liability	-$6.02M	-1.67M	-54.25%	$3.60	1.41M	Jan 7, 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CLOV	Restricted Stock Unit	Options Exercise		-3.34M	-50%		3.34M	Jan 7, 2025	Class B Common Stock	3.34M		Direct	F1, F3
transaction	CLOV	Class B Common Stock	Options Exercise		+3.34M	+63.88%		8.58M	Jan 7, 2025	Class A Common Stock	3.34M		Direct	F1, F2
transaction	CLOV	Class B Common Stock	Options Exercise		-1.67M	-19.49%		6.9M	Jan 7, 2025	Class A Common Stock	1.67M		Direct	F1, F2
holding	CLOV	Class B Common Stock						75.7M	Jan 7, 2025	Class A Common Stock	75.7M		Held by NJ Healthcare Investment, LLC	F1, F4
holding	CLOV	Class B Common Stock						182K	Jan 7, 2025	Class A Common Stock	182K		Held by Titus Ventures, LLC	F1, F4
holding	CLOV	Class B Common Stock						5.65M	Jan 7, 2025	Class A Common Stock	5.65M		Held by Ceasar Ventures, LLC	F1, F4
holding	CLOV	Class B Common Stock						2.06M	Jan 7, 2025	Class A Common Stock	2.06M		Held by Ceasar Clover, LLC	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer.
F2	On January 7, 2025, 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,671,733 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,670,695 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event.
F3	Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vests in equal installments on the first five anniversaries of January 7, 2021.
F4	The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC, Titus Ventures, LLC, Caesar Ventures, LLC and Caesar Clover, LLC.